发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
Novo CEO Says Drugmaker Has Overpromised, Underdelivered Novo is facing patent expiration in the US and Europe for Ozempic and Wegovy, a franchise that’s currently pulls in about three-quarters of its sales.
发布时间
16 天前
2026-09-22 07:22:14 UTC
源站更新
16 天前
2026-09-22 07:58:16 UTC
首次抓取
16 天前
2026-09-22 08:13:04 UTC
诺和诺德首席执行官迈克·道斯达表示，公司过去承诺过多、交付不足，迅速失去投资者信任。公司面临奥泽姆匹克和威戈维专利到期，面临收入大幅下滑风险。
Novo Nordisk CEO Mike Doustdar admits the company has overpromised and underdelivered, eroding investor trust. Facing patent expirations for Ozempic and Wegovy, Novo is seeking external assets in obesity-related areas while investors demand more visibility into next-generation
用于追踪这条内容的来源与记录标识。
